{"id":"ac-170-0-05","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Hypoglycemia"}]},"_chembl":{"chemblId":"CHEMBL1000","moleculeType":"Small molecule","molecularWeight":"388.90"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AC-170 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is associated with several potential therapeutic benefits, including improved glycemic control and potential cardiovascular benefits.","oneSentence":"AC-170 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:31.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04706559","phase":"NA","title":"Efficacy of Oral Supplementation of Probiotics in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","startDate":"2021-01-03","conditions":"Atopic Dermatitis","enrollment":98},{"nctId":"NCT01332188","phase":"PHASE2, PHASE3","title":"Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model","status":"COMPLETED","sponsor":"Aciex Therapeutics, Inc.","startDate":"2011-04","conditions":"Allergic Conjunctivitis","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AC-170 0.05%","genericName":"AC-170 0.05%","companyName":"Aciex Therapeutics, Inc.","companyId":"aciex-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AC-170 0.05% is an intervention studied in clinical trials for conditions such as Atopic Dermatitis and Allergic Conjunctivitis. The trials involve comparing AC-170 0.05% to conventional treatment and a probiotic sachet containing a mixture of four strains.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}